PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27622543-5	2016	induced ptosis under treatment with 3-hydroxybenzylhydrazine, a centrally acting AADC inhibitor.	3-hydroxybenzylhydrazine	36-60	dopa decarboxylase	Mus musculus	81-85	
18582514-5	2008	The synthesis of dopamine from L-DOPA supplied to Muller cultures is inhibited by m-hydroxybenzylhydrazine, a DDC inhibitor.	3-hydroxybenzylhydrazine	82-106	dopa decarboxylase	Mus musculus	110-113	
32671919-11	2020	In addition, l-dopa reduced corticotrophin-releasing hormone-stimulated adrenocorticotrophic hormone release from these cells after AADC activity was inhibited by NSD-1015.	3-hydroxybenzylhydrazine	163-171	dopa decarboxylase	Mus musculus	132-136	
32522342-6	2020	Importantly, treatment with AADC inhibitor NSD-1015 significantly ameliorated EAP-elicited pain response and catecholamine overactivity in MTA1-/- mice.	3-hydroxybenzylhydrazine	43-51	dopa decarboxylase	Mus musculus	28-32